NCT00520897View on ClinicalTrials.gov

Integrase Inhibitor (MK-0518) Viral Decay

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

November 30, 2011

Conditions
HIV Infections
Interventions
DRUG

Raltegravir (MK0518)

400mg BID; 48 weeks

DRUG

Placebo

400mg QD

PROCEDURE

Leukopheresis

pack of cells as per protocol

PROCEDURE

Sigmoid Biopsy

gut samples as per protocol

Trial Locations (1)

M5B 1L6

Maple Leaf Medical Clinic, Toronto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Canadian Immunodeficiency Research Collaborative

OTHER

NCT00520897 - Integrase Inhibitor (MK-0518) Viral Decay | Biotech Hunter | Biotech Hunter